

**A**

**B**

**C**

**D**

**E**

**F**

**G**

**H**

**I**

**J**

**K**

**L**

**M**

**N**

**O**

**P**

Supplemental Digital Content 2. XOR activity and purine metabolites were unaffected by H2 treatment during hemorrhagic shock. (A) – (D), XOR activity; (E) – (H), hypoxanthine concentration; (I) – (L), xanthine concentration; (M) – (P), uric acid concentration. XOR activity and purine metabolite concentrations were similar between H2 and control groups at the end of the shock phase. N ≥ 10 animals in each group. HS, hemorrhagic shock; HS/R, hemorrhagic shock and resuscitation; XOR, xanthine oxidoreductase; XOR-I, XOR-inhibitor.



**A**

**B**

**C**

**D**

**E**

**F**

**G**

**H**

**I**

**J**

**K**

**L**

**M**

**N**

**O**

**P**

Supplemental Digital Content 3. XOR activity and purine metabolites were unaffected by H2 treatment after fluid resuscitation. (A) – (D), XOR activity; (E) – (H), hypoxanthine concentration; (I) – (L), xanthine concentration; (M) – (P), uric acid concentration. XOR activity and purine metabolite concentrations of plasma and organs were similar between H2 and control groups. N ≥10 animals in each group. H2, hydrogen gas; HS/R, hemorrhagic shock and resuscitation; XOR, xanthine oxidoreductase.